Radiation-induced oral mucositis — radiation-induced oral mucositis: pathogenesis, risk factors, clinical manifestations, prevention, and treatment

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This study presents the modern concepts of pathogenesis, risk factors, etiology, clinical manifestations, prevention, and treatment of oropharyngeal mucositis, one of the main complications of radiation therapy for head and neck region cancer. The leading role in the mechanisms of disease development belongs to rapidly dividing cells of the basal layer of the oropharyngeal mucous membrane. This damage is due to both direct (excitation and ionization) and indirect (accumulation of active oxygen and nitrogen compounds, activation of transcription factors, hyperfunction of pro-inflammatory cytokines, etc.) action of ionizing radiation on the most important biological molecules and supramolecular structures (polynucleotides, nucleoproteins, phospholipids, etc.). The main risk factors for mucositis include the localization and size of the tumor, the amount of radiation dose to the oral region, and individual body characteristics (young age, pernicious habits, metal structures of dentures, a history of periodontal disease, etc.). The disease severity is described from mild (erythema and moderate pain that does not require analgesia) to severe (ulceration, hemorrhage, necrosis, and other symptoms) to establishment necessary prescription of effective means of pathogenetic and symptomatic therapy. The main means and methods of prevention of radiation-induced mucositis include the following: non-steroidal anti-inflammatory drug benzydamine, means of protection against oxidative stress glutamine, and drugs with a complex stimulating effect on wound healing processes. Drug therapy for mucositis involves the use of benzydamine; the tricyclic antidepressant doxepin; and a gel consisting of polyvinylpyrrolidone (Belclaiz), mucolytic acetylcysteine. When non-narcotic analgesics are ineffective, low doses of opiates (fentanyl, morphine, and methadone) are used in oral, transdermal, or parenteral dosage forms, as well as low-intensity laser therapy. The most important components of the etiopathogenetic therapy of the disease include antiviral drugs (acyclovir and valacyclovir) and fungicides (clotrimazole, fluconazole, and itraconazole). Enteral nutrition difficulty indicates nasogastric or nasojejunal tube usage, and in more serious cases, surgical methods such as gastro- or jejunostomy.

Full Text

Restricted Access

About the authors

Vladimir I. Legeza

Military Medical Academy named after S.M. Kirov of the Ministry of Defense of the Russian Federation

Email: Legeza@mail.ru
ORCID iD: 0000-0002-1086-8247
SPIN-code: 5679-3227

doctor of medical sciences, professor

Russian Federation, Saint Petersburg

Alexander E. Antushevich

Military Medical Academy named after S.M. Kirov of the Ministry of Defense of the Russian Federation

Email: Antushevich@mail.ru
SPIN-code: 8947-6154

doctor of medical sciences, professor

Russian Federation, Saint Petersburg

Andrey G. Klimov

Military Medical Academy named after S.M. Kirov of the Ministry of Defense of the Russian Federation

Email: alexklim1957@mail.ru
SPIN-code: 6178-2223

doctoral student

Russian Federation, Saint Petersburg

Gennady G. Zagorodnikov

Military Medical Academy named after S.M. Kirov of the Ministry of Defense of the Russian Federation

Email: Zagorodnikov@mail.ru
SPIN-code: 4465-5572

doctor of medical sciences

Russian Federation, Saint Petersburg

Vladimir M. Reznik

Military Medical Academy named after S.M. Kirov of the Ministry of Defense of the Russian Federation

Email: Askold9@mail.ru
ORCID iD: 0000-0001-6083-2667
SPIN-code: 3558-2740

candidate of medical sciences

Russian Federation, Saint Petersburg

Natalia V. Aksenova

Military Medical Academy named after S.M. Kirov of the Ministry of Defense of the Russian Federation

Author for correspondence.
Email: vmeda-nio@mil.ru
ORCID iD: 0000-0002-5645-7072
SPIN-code: 6821-6887

candidate of medical sciences

Russian Federation, Saint Petersburg

References

  1. Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66(3):253–262. doi: 10.1016/S0167-8140(02)00404-8
  2. Elting LS, Keefe DM, Sonis ST, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy. Cancer. 2008;113(10):2704–2713. doi: 10.1002/cncr.23898
  3. Vera-Llonch M, Oster G, Hagiwara M, Sonis S. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer. 2006;106(2):329–336. doi: 10.1002/cncr.21622
  4. Squier CA, Kremer MJ. Biology of oral mucosa and esophagus. J Natl Cancer Inst Monogr. 2000;29:7–15. doi: 10.1093/oxfordjournals.jncimonographs.a003443
  5. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;(4):277–284. doi: 10.1038/nrc1318
  6. Kumar PS, Balan A, Sankar A, Bose T. Radiation induced oral mucositis. Indian J Palliat Care. 2009;15(2):95. doi: 10.4103/0973-1075.58452
  7. Antushevich AE, Yartseva AA, Antonov VG, et al. The effect of molixan on the activity of redox processes in the oral mucosa of experimental animals with combined chemoradiation. Bulletin of the Russian Military Medical Academy. 2014;(1):152–155. (In Russ.).
  8. Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients who have cancer. Dent Clin N Am. 2008;52(1):61–77. doi: 10.1016/j.cden.2007.10.002
  9. Shih A, Miaskowski C, Dodd MJ, et al. Mechanisms for radiation-induced oral mucositis and the consequences. Cancer Nurs. 2003;26(3):222–229. doi: 10.1097/00002820-200306000-00008
  10. Yartseva AA, Stepanov AV, Antushevich AE, et al. The state of the microbiocenosis of the oral cavity of experimental animals exposed to the combined effects of damaging factors of chemoradiation therapy. Bulletin of the Russian Military Medical Academy. 2014;(1):105–109. (In Russ.).
  11. PDQ Supportive and Palliative Care Editorial Board. Oral complications of chemotherapy and head/neck radiation (PDQ®): Health Prifessional Version 2016. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US). 2021 Jul 14.
  12. Seiwert TY, Salama JK, Vokes EE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol. 2007;4(3):156–171.
  13. Walsh L, Gillham C, Dunne M, et al. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). Radiother Oncol. 2011;98(1):38–41. doi: 10.1038/ncponc0750
  14. Meirovitz A, Kuten M, Billan S, et al. Cytokines levels, severity of acute mucositis and the need of PEG tube installation during chemo-radiation for head and neck cancer-a prospective pilot study. Radiat Oncol. 2010;5(1):1. doi: 10.1016/j.radonc.2010.11.009
  15. Xanthinaki A, Nicolatou-Galitis O, Athanassiadou P, et al. Apoptotic and inflammation markers in oral mucositis in head and neck cancer patients receiving radiotherapy: preliminary report. Supp Care Cancer. 2008;16:1025–1033. doi: 10.1186/1748-717X-5-16
  16. Haddad R, Sonis S, Posner M, et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer. 2009;115(19):4514–4523. doi: 10.1007/s00520-007-0379-8
  17. Suresh A, Varma PP, Sinha S, et al. Risk-scoring system for predicting mucositis in patients of head and neck cancer receiving concurrent chemoradiotherapy [rssm-hn]. J Cancer Res Ther. 2010;6(4):448. doi: 10.1002/cncr.24525
  18. Sonis S. Oral mucositis in head and neck cancer: risk, biology, and management. Am Soc Clin Oncol Educ Book. doi: 10.1200/EdBook_AM.2013.33.e236
  19. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, National Institutes of Health, National Cancer Institute. Сommon terminology criteria for adverse events v 4.0. National Cancer Institute, Bethesda. MD. 2009.
  20. Taylor S. Guidelines for prevention and management of oral mucositis. West Sussex and Hampshire Cancer Network NHS, Surrey. 2014.
  21. Lalla RV, Schubert MM, Bensadoun RJ, Keefe D. Anti-inflammatory agents in the management of alimentary mucositis. Supp Care Cancer. 2006;14(6):558–565. doi: 10.1007/s00520-006-0050-9
  22. Kazemian A, Kamian S, Aghili M, et al. Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial. Eur J Cancer Care. 2009;18(2):174–178. doi: 10.1111/j.1365-2354.2008.00943.x
  23. Sheibani KM, Mafi AR, Moghaddam S, et al. Efficacy of benzydamine oral rinse in prevention and management of radiation-induced oral mucositis: a double-blind placebo-controlled randomized clinical trial. Asia Pac J Clin Oncol. 2015;11(1):22–27. doi: 10.1111/ajco.12288
  24. Jadaud E, Bensadoun R. Low-level laser therapy: a standard of supportive care for cancer therapy-induced oral mucositis in head and neck cancer patients. Laser Ther. 2012;21(4):297. doi: 10.5978/islsm.12-RE-01
  25. Barrett S. A skeptical look at low level laser therapy. Quackwatch. 2010.
  26. Savarese DM, Savy G, Vahdat L, et al. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev. 2003;29(6):501–513. doi: 10.1016/S0305-7372(03)00133-6
  27. Antushevich AE, Yartseva AA, Bolekhan AV, et al. Antiradiation activity of preparations containing glutathione disulfides. Bulletin of the Russian Military Medical Academy. 2019;(1):127–131. (In Russ.)
  28. Chattopadhyay S, Saha A, Azam M, et al. Role of oral glutamine in alleviation and prevention of radiation-induced oral mucositis: a prospective randomized study. South Asian J Cancer. 2014;3(1):8. doi: 10.4103/2278-330X.126501
  29. Silverman S Jr. Diagnosis and management of oral mucositis. J Support Oncol. 2007;5(2):13–21.
  30. Tsujimoto T, Yamamoto Y, Wasa M, et al. L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial. Oncol Rep. 2015;33(1):33–39. doi: 10.3892/or.2014.3564
  31. Brian D, Lawenda MD. Use glutamine to reduce the severity of mucositis and neuropathy (during chemotherapy or radiation therapy). Integrat Oncol Essent. 2013;25.
  32. Moslemi D, Babaee N, Damavandi M, et al. Oral zinc sulphate and prevention of radiation-induced oropharyngealmucositis in patients with head and neck cancers: a double blind, randomized controlled clinical trial. Int J Radiat Res. 2014;12(3):235–241.
  33. Babaee N, Moslemi D, Khalilpour M, et al. Antioxidant capacity of Calendula officinalis flowers extract and prevention of radiation induced oropharyngeal mucositis in patients with head and neck cancers: a randomized controlled clinical study. DARU J Pharmaceut Sci. 2013;21(1):1. doi: 10.1186/2008-2231-21-18
  34. Babaee N, Moslemi D, Khalilpour M, et al. Investigation of the effect of Calendula officinalis extract on preventing radiotherapy-induced oral mucositis. Reports of Radiotherapy and Oncology. 2013;1(1).
  35. Hawley P, Hovan A, McGahan CE, Saunders D. A randomized placebo-controlled trial of manuka honey for radiation-induced oral mucositis. Supp Care Cancer. 2014;22(3):751–761. doi: 10.1007/s00520-013-2031-0
  36. Masucci G, Broman P, Kelly C, et al. Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy. Med Oncol. 2005;22(3):247–256. doi: 10.1385/MO:22:3:247
  37. Barasch A, Epstein J, Tilashalski K. Palifermin for management of treatment-induced oral mucositis in cancer patients. Biologics. 2009;3:111–116. doi: 10.2147/BTT.S3914
  38. Brizel DM, Murphy BA, Rosenthal DI, et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol. 2008;26(15):2489–2496. doi: 10.1200/JCO.2007.13.7349
  39. Hong J, Song S, Ahn S, et al. (Recombinant human epidermal growth factor treatment of radiation-induced severe oral mucositis in patients with head and neck malignancies. Eur J Cancer Care. 2009;18(6):636–641. doi: 10.1111/j.1365-2354.2008.00971.x
  40. Ara G, Watkins BA, Zhong H, et al. Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation. Int J Radiat Biol. 2008;84(5):401–404. doi: 10.1080/09553000802007601
  41. Roopashri G, Jayanthi K, Guruprasad R. Efficacy of benzydamine hydrochloride, chlorhexidine, and povidone iodine in the treatment of oral mucositis among patients undergoing radiotherapy in head and neck malignancies: a drug trail. Contemp Clin Den. 2011;2(1):8–12. doi: 10.4103/0976-237X.79292
  42. Leenstra JL, Miller RC, Qin R, et al. Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a phase III, randomized, double-blind trial (NCCTG-N09C6 [alliance]). J Clin Oncol. 2014;32(15):1571–1577. doi: 10.1200/JCO.2013.53.2630
  43. Berger AM, Shuster JL, Von Roenn JH. Principles and practice of palliative care and supportive oncology. Philadelphia, PA: Lippincott, Williams & Wilkins; 2013.
  44. Gupta A, Duckles B, Giordano J. Use of sublingual methadone for treating pain of chemotherapy-induced oral mucositis. J Opioid Manag. 2009;6(1):67–69. doi: 10.5055/jom.2010.0007
  45. Sarvizadeh M, Hemati S, Meidani M, et al. Morphine mouthwash for the management of oral mucositis in patients with head and neck cancer. Adv Biomed Res. 2015;4:44. doi: 10.4103/2277-9175.151254
  46. Jham BC, da Silva Freire AR. Oral complications of radiotherapy in the head and neck. Rev Bras Otorrinolaringol. 2006;72(5):704–708. doi: 10.1016/S1808-8694(15)31029-6
  47. Lowry F. Laser treatment halts oral mucositis in its tracks. Oncology Nursing Society (ONS) 40th Annual Congress. 2015.
  48. Nicolatou-Galitis O, Athanassiadou P, Kouloulias V, et al. Herpes simplex virus-1 (HSV-1) infection in radiation-induced oral mucositis. Supp Care Cancer. 2006;14(7):753–762. doi: 10.1007/s00520-005-0006-5
  49. Bar Ad V, Weinstein G, Dutta PR, et al. Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. Cancer. 2010;116(17):4206–4213. doi: 10.1002/cncr.25274
  50. Fitzmorris KL, Greene JN, Sandin RL, Field T. Recognition and management of herpes simplex mucositis in neutropenic patients. Inf Med. 2000;17(6):413–416.
  51. Deng G, Cassileth BR. Supportive care and quality of life. Perez and Brady’s principles and practice of radiation oncology. 6th edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2013. Section V, Chapter 97.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2021 Legeza V.I., Antushevich A.E., Klimov A.G., Zagorodnikov G.G., Reznik V.M., Aksenova N.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 77762 от 10.02.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies